The brand new treatment, an injectable form of the enzyme, collagenase, that significantly improves outcomes in lots of patients with the condition, may be the first FDA-approved non-surgical treatment for Dupuytren’s disease. Drs Badalamente and Hurst will discuss the brand new treatment approach at the meeting. The CME system will take place at SBUMC’s Health Sciences Center, Level 2, Lecture Hall 1. Periods shall run from 8:00 AM to 5:30 PM.. CME plan for understanding most recent treatment and research in Dupuytren’s disease The Department of Orthopaedics at Stony Brook University INFIRMARY and the Office of Continuing Medical Education will run a CME program for hand surgeons, hand therapists, rheumatologists, researchers and others interested in understanding the most recent treatment and research on Dupuytren’s disease, a debilitating hand disorder caused by progressive accumulation of collagen that deforms fingers and limits movement and affects millions worldwide.The effect on in-the-field HIV diagnostics by itself could be revolutionary; this financing is critical to your commercialization roadmap. ChipCare's Phase II task plan calls for a three-year advancement of the device to further refine its functionality, create a better quality prototype and keep your charges down, as part of the move to level. The innovative financing model supporting this advancement was permitted, in part, with the leadership of the federal government of Canada through Grand Issues Canada. This initiative underscores our federal government's commitment to aid innovation, leverage personal sector know-how, and harness venture capital expertise in search of game-changing advancement and global health solutions.